Entity

Time filter

Source Type


Gong X.-J.,Qingdao University | Song X.-Y.,Peoples Hospital of Rizhao | Wei H.,Peoples Hospital of Zhangqiu | Niu M.,Qingdao University
European Review for Medical and Pharmacological Sciences | Year: 2015

OBJECTIVE: Myocardial infarction causes significant mortality and morbidity. Timely diagnosis allows clinicians to risk stratify their patients and select appropriate treatment. Biomarkers have been used to assist with timely diagnosis, while an increasing number of novel markers have been identified to predict outcome following an acute myocardial infarction or acute coronary syndrome. The objective of this study was to determine S100A4 expression in AMI and determine whether S100A4 could be a biomarker for detection of acute myocardial infarction (AMI). PATIENTS AND METHODS: We measured circulating S100A4 levels in 173 patients (median age 58.3 years) who presented with first-time AMI 8 hours after the incident. The circulating S100A4 levels in 173 healthy volunteers (median age 57.3 years) was also measured. S100A4 was detected using enzyme immunoassay in both groups. RESULTS: Serum S100A4 levels were significantly higher in patients with AMI [89.6 (4.3-214.6) pg/ml] compared to controls [11.8 (0-41.5) pg/ml] (p < 0.001). We found that a S100A4 level > 41.5 pg/ml had a Sensitivity 76.3% and specificity 87.5% for predicting AMI. S100A4 revealed the higher sensitivity for diagnosing AMI. CONCLUSIONS: Elevated S100A4 in plasma may be a novel biomarker for early detection of AMI. Source


Li B.,Jinan General Hospital | Wang H.,Jinan General Hospital | Wu H.,Peoples Hospital of Zhangqiu | Gao C.,Jinan General Hospital
Medicine (United States) | Year: 2015

Many studies have reported the beneficial effects of dexmedetomidine on postoperative neurocognitive function but overall evidence is not as clear. We examined this conundrum by meta-analyzing studies that used dexmedetomidine in perioperative conditions or as intensive care unit (ICU) sedation and utilized reliable neurocognitive assessment tests. The literature search was undertaken across several electronic databases including EBSCO, Embase, Google Scholar, Ovid SP, PubMed, Scopus, and Web of Science. Literature search was carried out across several electronic databases and relevant studies were selected after following précised inclusion criteria. Meta-analysis of risk differences (RDs) was carried out and subgroup analyses were performed. Twenty studies were selected from which data of 2612 individuals were used. Initial dexmedetomidine dose was 0.68±0.27 and maintenance dose was 0.54±0.32 in the trials. Dexmedetomidine treatment was associated with significantly lower risk of postoperative/postanesthesia neurocognitive dysfunction both in comparison with saline-treated controls (RD [95% confidence interval, CI]:-0.17 (-0.30,-0.04); P=0.008) and comparators (-0.16 [-0.28,-0.04]; P=0.009). In the subgroups analyses, however, there was no significant differences between dexmedetomidine and controls/comparators when studies with confusion assessment method for ICU only (RD:-0.10 (-0.22, 0.02); P=0.1) or midazolam as comparator only (RD:-0.26 (-0.60, 0.07); P=0.12) were meta-analyzed. Dexmedetomidine use in the perioperative conditions or as ICU sedation is associated with lower risk of neurocognitive dysfunction. There can be some impact of neurocognitive assessment method, drug interactions, and clinical heterogeneity on the overall outcomes of this meta-analysis. © 2015 Wolters Kluwer Health, Inc. All rights reserved. Source


Zhang Q.-H.,Shandong University | Dou H.-T.,Central Hospital of Zibo | Xu P.,Peoples Hospital of Zhangqiu | Zhuang S.-C.,Central Hospital of Zibo | Liu P.-S.,Shandong University
Drug Research | Year: 2015

Introduction: The presence of subset of cancer stem cells (CSCs) called Side population (SP) cells has been identified in several solid tumors, responsible for treatment failure especially chemotherapy, and cancer relapse. The present study was aimed to isolate and characterize cancer stem like cells side population cells from high grade ovarian cancer. Methods: The collected cancer samples were analyzed for presence of SP cells by FACS using Hoechst 33342 exclusion technique. Further the FACS sorted SP and non-SP cells were subjected to analysis of stem cell surface protein expression by western blot and immunocytochemistry, drug resistance and sphere formation assay. Results: By FACS, we have identified 3.7% of cancer stem cell like side population cells in ovarian cancer whose prevalence was reduced to 0.5% upon treatment with verapamil an inhibitor of ABC transporter. Further, these sorted SP cells showed over expression of ABCG2 (ABC transporter), stem cell proteins such as CD144, CD44, EpCAM and antiapoptotic factor Bcl-2. Also the SP cells showed high resistance to chemotherapy drugs, have high survival rate and they are highly potential to form tumor spheres. Conclusion: Our data suggest that ovarian cancer contain small sub-population of side population cells which shares some characteristics of stem cells. The co-expression of ABC transporters and stem cells surface markers in SP cells may associate with resistance to chemotherapeutic agents, apoptosis and also supports a role for these cells in tumor recurrence, metastasis and invasion. © Georg Thieme Verlag KG Stuttgart. New York. Source


Cai H.,Peoples Hospital of Zhangqiu | Wang H.,The Affiliated Hospital of Weifang Medical College
World Journal of Surgical Oncology | Year: 2015

Background: In a previous analysis using a lung cancer cell line model, we have found that therapies directed against secreted clusterin (sCLU) and its downstream signaling targets pAkt and pERK1/2 may have the potential to enhance the efficacy of cisplatin (DDP)-based chemotherapy in vitro. Here, we investigated the therapies directed against sCLU on the DDP-based chemotherapy in vivo and explored the mechanism. Methods: Using lung cancer cell lines, A549 cells and DDP-resistant A549 cells (A549DDP), we determined the effect of sCLU silencing using short interfering double-stranded RNA (siRNA) on chemosensitivity in immunocompromised mice bearing A549DDP tumors. We then determined the effect of sCLU overexpression via stable sCLU transfection on chemosensitivity in immunocompromised mice bearing A549 tumors. The effect of sCLU silencing or overexpression on pAkt and pERK1/2 expression and chemosensitivity in vivo was detected by Western blot assay. Results: The results showed sCLU silencing increased the chemosensitivity of A549DDP cells to DDP in vivo via downregulation of pAkt and pERK1/2 expression. And sCLU overexpression decreased the chemosensitivity of A549 cells to DDP in vivo via upregulation of pAkt and pERK1/2 expression. Conclusions: We therefore concluded that the DDP-induced sCLU activation, which involved induction of pAkt and pERK1/2 activation that confer DDP resistance in immunocompromised mice and alteration of this balance, allows sensitization to the antitumor activity of cisplatin chemotherapy. © 2015 Ma et al., licensee BioMed Central. Source


Zhang X.,Second Hospital of Qinhuangdao | Huang X.,Peoples Hospital of Zhangqiu | Shao X.,Hebei Medical University
Journal of Hand Surgery | Year: 2015

This article reports on a percutaneous joystick technique for reduction of fifth metacarpal neck fractures. The technique was performed in 76 hands. Reduction was achieved in all cases. The technique is a useful reduction maneuver in the treatment of fifth metacarpal neck fractures. © 2015 American Society for Surgery of the Hand. Source

Discover hidden collaborations